Silence gets green light for siRNA trial

The UK's Silence Therapeutics has won regulatory approval to begin an early-stage human trial that will for the first time test the infusion of one of its gene silencing therapies directly to the site of the illness. "The big challenge in this area is to deliver (the drug)," CEO Iain Ross tells Reuters. "This is a systemically delivered product, given by infusion. This is a major step forward." Silence Therapeutics is partnered with Pfizer and AstraZeneca in human trials that put short interfering RNA therapies directly on the treatment site. The upcoming Phase I trial in Germany will test Silence's Atu027 for advanced solid malignant tumors. Atu027 specifically targets PKN3, a molecule involved in cancer growth and metastasis formation. Release | Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.